Phase 2 Clinical Trial of Imetelstat in Essential Thrombocythemia, Geron (GERN)
January 19th, 2011
No comments
GERN enrolled the 1st patient in a P2 clinical trial to evaluate the activity of its telomerase inhibitor drug, imetelstat (GRN163L) Read more…
Categories: NASDAQ: GERN, P2 imetelstat (GRN163L) trial, Stem Cell Technology
